Children in Real-world Setting Have Different Orkambi Response Profiles
Children with cystic fibrosis (CF) being treated with Orkambi (ivacaftor/lumacaftor) have distinct clinical response profiles after six months of treatment in a real-world setting, a French-Italian study found. While changes in lung function were the largest driver of treatment responses in older children ages 12–18, body mass index…